Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study.

Ardavanis A, Doufexis D, Kountourakis P, Malliou S, Karagiannis A, Kardara E, Sykoutri D, Charalampia M, Rigatos G.

BMC Cancer. 2009 Sep 23;9:338. doi: 10.1186/1471-2407-9-338.

2.

A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Orphanos G, Alexopoulos A, Malliou S, Ioannidis G, Ardavanis A, Kandylis C, Stavrakakis J, Rigatos G.

J Cancer Res Clin Oncol. 2010 Jan;136(1):115-21. doi: 10.1007/s00432-009-0642-0.

PMID:
19672628
3.

Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.

Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, Fragos I, Rigatos G.

Anticancer Res. 2008 Sep-Oct;28(5B):3087-92.

4.

Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.

Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, Kardara E, Frangos I, Koumna S, Baziotis N, Scorilas A, Ardavanis A.

J BUON. 2008 Jul-Sep;13(3):409-13.

PMID:
18979558
5.

Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity.

Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, Scorilas A, Rigatos G.

Anticancer Res. 2008 Jul-Aug;28(4C):2409-15.

6.

Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.

Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G.

Oncologist. 2008 Apr;13(4):361-9. doi: 10.1634/theoncologist.2007-0207.

Supplemental Content

Loading ...
Support Center